Latest Technology Platforms News

Bell Financial Group reported a 44% drop in half-year net profit to $9.3 million, driven by a sharp decline in broking revenues, while its Technology & Platforms and Products & Services divisions delivered robust growth.

Viva Leisure has reported a robust FY2025 with record membership and a 30% jump in revenue, driven by strategic acquisitions and a booming technology segment. The company’s multi-brand approach and expanding network position it strongly for future growth.

Thrive Tribe Technologies has raised approximately $250,000 through a discounted share placement and repaid nearly $100,000 in loans by issuing shares, aiming to bolster working capital.

Articore Group Limited reported a notable turnaround in FY25 with improved margins and its first profitable quarter in five years, setting the stage for positive EBIT in FY26. The company’s strategic restructuring and supply chain efficiencies underpin cautious optimism for growth.

Articore Group reports a milestone fourth quarter with record gross profit margins and positive EBIT, setting the stage for a profitable FY26. The company’s disciplined turnaround strategy shows tangible progress despite ongoing marketplace revenue challenges.

Origin Energy reported a 6% rise in full-year profit to $1.48 billion, driven by LNG trading gains and operational resilience, while advancing key renewable projects and battery storage developments.

Talga Group has launched Talnode-R, a recycled graphite anode product derived from lithium-ion battery waste, aiming to transform battery supply chains with sustainable, modular production.

Insurance Australia Group (IAG) reported a robust 51.3% increase in net profit after tax for FY25, driven by premium growth, operational efficiencies, and favourable natural peril experience. The company also announced strategic alliances with RACQ and RAC, poised to significantly expand its market footprint.

Syntara Limited has received FDA guidance recommending a Phase 2 controlled trial for its lead drug amsulostat in myelofibrosis, setting the stage for a pivotal Phase 3 study. The company is poised to refine its clinical strategy while advancing a diverse pipeline with key data milestones ahead.

Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Shift4 Payments has secured Overseas Investment Office approval for its NZ$1.20 per share acquisition of Smartpay, advancing the proposed scheme of arrangement closer to completion.